Resistance gene expression determines the in vitro chemosensitivity of non-small cell lung cancer (NSCLC)

BMC Cancer

Table 4 Data for each drug and combination tested, showing median and interquartile range (in brackets) for IC50, IC90 (both expressed as % TDC) and Index_SUM.

Drug/Combination	IC90 (%TDC)	IC50 (%TDC)	Index_SUM	Number with > 95% inhibition
Docetaxel	433 297 – 778.5	246 71 – 438	523 419 – 591	0/43
Cisplatin	229 204 – 278	95 71 – 156	466 378 – 513	0/41
Gemcitabine	300 242 – 383	82 22 – 213	378 293 – 446	0/39
Cisplatin with Gemcitabine	80 46 – 143	13 8 – 23	186 136 – 231	19/38
Docetaxel with Cisplatin	213 203 – 231	75 59 – 93	378 339 – 405	0/22
Docetaxel with Gemcitabine	242 224 – 267	45 37 – 78	310 290 – 370	0/21

The final column shows the number of tumors tested and those achieving 95% inhibition at the 100% TDC of those tested for each drug or combination.

ISSN: 1471-2407